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Abstract
The 3-Deazaneplanocin A (DZNep), one of S-adenosylhomocysteine (AdoHcy) hydrolase inhibitors, has shown antitumor
activities in a broad range of solid tumors and acute myeloid leukemia. Here, we examined its effects on multiple myeloma
(MM) cells and found that, at 500 nM, it potently inhibited growth and induced apoptosis in 2 of 8 MM cell lines. RNA from
un-treated and DZNep treated cells was profiled by Affymetrix HG-U133 Plus 2.0 microarray and genes with a significant
change in gene expression were determined by significance analysis of microarray (SAM) testing. ALOX5 was the most
down-regulated gene (5.8-fold) in sensitive cells and was expressed at low level in resistant cells. The results were
corroborated by quantitative RT-PCR. Western-blot analysis indicated ALOX5 was highly expressed only in sensitive cell line
H929 and greatly decreased upon DZNep treatment. Ectopic expression of ALOX5 reduced sensitivity to DZNep in H929
cells. Furthermore, down-regulation of ALOX5 by RNA interference could also induce apoptosis in H929. Gene expression
analysis on MM patient dataset indicated ALOX5 expression was significantly higher in MM patients compared to normal
plasma cells. We also found that Bcl-2 was overexpressed in DZNep insensitive cells, and cotreatment with DZNep and ABT-
737, a Bcl-2 family inhibitor, synergistically inhibited growth and induced apoptosis of DZNep insensitive MM cells. Taken
together, this study shows one of mechanisms of the DZNep efficacy on MM correlates with its ability to down-regulate the
ALOX5 levels. In addition, DZNep insensitivity might be associated with overexpression of Bcl-2, and the combination of
ABT-737 and DZNep could synergistically induced apoptosis. These results suggest that DZNep may be exploited
therapeutically for a subset of MM.
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Introduction
The 3-Deazaneplanocin A (DZNep) is the cyclopentanyl analog
of 3-deazaadenosine that inhibits the activity of S-adenosyl-L
homocysteine (AdoHcy) hydrolase, the enzyme responsible for the
reversible hydrolysis of AdoHcy to adenosine and homocysteine
[1,2]. Inhibition of AdoHcy hydrolase results in the cellular
accumulation of AdoHcy, which leads to inhibition of S-adonosyl-
L-methionine-dependent methyltransferase (MTase) activity.
DZNep has been explored for antiviral treatment and has been
reported to have minimal toxicity in vivo [3,4,5]. Recently,
DZNep was reported to decrease levels of the PRC2 protein
complex in breast cancer cells and inhibit associated histone
H3K27Me3. It induced efficient apoptotic cell death in cancer
cells but not in normal cells [6]. DZNep was also shown to deplete
PRC2 complex, decrease levels of H3K27Me3, and induce
apoptosis of cultured and primary acute myeloid leukemia
(AML) cells. Furthermore, cotreatment with DZNep and the
pan-histone deacetylase inhibitor panobinostat induced synergistic
apoptosis of cultured and primary AML cells [7]. These make
DZNep a possible candidate as an epigenetic therapeutic for the
treatment of cancer.
Multiple myeloma (MM) is a malignant plasma cell disorder
that accounts for 0.8% of all cancers worldwide[8]. Incidence rates
vary from 0.4 to 5 per 100 000, and is high in North America,
Australia/New Zealand, northern Europe, and western Europe
compared with Asian countries [8]. Median survival for patients
with MM after conventional treatments is 3–4 years; high-dose
treatment followed by autologous stem-cell transplantation can
extend median survival to 5–7 years [9]. As such, the development
of innovative therapies and identification of more effective drugs
remain high priorities for MM research. Because of its antitumor
properties, DZNep holds promise as a treatment for MM. To
advance DZNep as anticancer agents, it is crucial to understand
the molecular mechanism and delineate markers that identify the
subset of tumors that are sensitive to DZNep-induced apoptosis. In
the study described here, we assayed a panel of MM cell lines and
showed that DZNep at low nanomolar concentratins potently
induced apoptosis in some of MM cell lines. We further
investigated the mechanisms of DZNep-induced apoptosis in
MM cells.
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        Materials and Methods
Cell lines and cell culture
Human MM cell lines KMS11, KMS12BM, KMS18, MM.1S,
RPMI-8226, OPM-2, U266 were maintained in RPMI 1640,
supplemented with 10% fetal bovine serum (FBS), 100 U/mL
penicillin and 100 mg/mL streptomycin. MM cell line NCI-H929
was cultured in RPMI 1640 with 15% FCS and 0.00036% 2-
mercaptoethanol. All cells were grown at 37 uC in a humidified
atmosphere with 5% CO2. All cells were gifts from Mayo clinic,
Scottsdale, AZ.
Drugs
DZNep was kindly provided by Prof. Yu Qiang, Genome
Institute of Singapore. The ABT-737, a Bcl-2 family inhibitor, was
kindly provided by Prof. Chen Chien-Shing, Loma Linda
University, CA. DZNep or ABT-737 was dissolved in neat
DMSO (Sigma-Aldrich ) at 10 mmol/L and stored as frozen
aliquots at 220uC. Caspase Inhibitor Z-VAD-FMK (Promega)
was dissolved in DMSO and stored at 220uC.
Cell proliferation assay and apoptosis analysis
Cells were seeded into 96-well plates at a density of
3.0610
4 cells/well in 50 mL culture medium. Then,50 mLo f
doubly concentrated drug solutions was added. Cells were
incubated at 37uC in a humidified, 5% CO2 atmosphere for
72 h, and subsequently analyzed using the MTS colorimetric assay
(Promega) as previously described [10]. The combination index
(CI) for DZNep and ABT-737 combination was obtained using
software CalcuSyn as described previously [11]. A CI of less than,
equal to, and more than 1 indicates synergy, additivity, and
antagonism, respectively. For apoptosis analysis, cells were treated
with 0.5 mM DZNep and cultured for 72 h. Then, cells were
pooled and analyzed for the level of apoptosis by flow cytometry
using propidium iodide (PI) staining as described previously
[12,13].
Microarray analysis and quantitative RT-PCR
Cells were treated with 0.5 mmol/L DZNep for 48 h. Total
RNA was extracted by using the Qiagen RNeasy Mini kit
(Germany). Gene expression was performed using the Gene-
ChipH Human Genome U133A Array (Affymetrix) following the
manufacturer’s instructions. Data analysis was performed using
GeneSpring software from Agilent Technologies. The data was
deposited in Gene Expression Omnibus with accession no.
GSE26921. The differentially expressed genes were grouped
using Panther Protein Classification [14]. Using oligo(dT)20
primer and reverse transcriptase, cDNA was created by using the
Invitrogen SuperScript III First-Strand Synthesis System. The
7300 Real-Time PCR System (Applied Biosystems, CA) was
used for real-time PCR amplification according to the Power
SYBRH Green PCR Master Mix protocol. Relative quantifica-
tion of gene expression was done as described in the manual
using b-Actin as an internal standard and the comparative
threshold cycle method. The primers for real-time PCR were
listed in Table S1.
Figure 1. MM cell lines display differing degrees of sensitivity to DZNep. (A) Cells were treated with various concentrations of DZNep for
72 h. The proliferation was determined by MTS colorimetric assay (Promega). Data represent the mean 6 SD derived from 3 separate experiments
with triplicate wells per condition. (B) Cells were treated with 0.5 mM DZNep for 72 h, and apoptosis was measured by flow cytometric sub-G1
analysis. Data represent the mean 6 SD derived from 3 separate experiments (one time for KMS12BM). * indicates p,0.05, and ** indicates p,0.01.
doi:10.1371/journal.pone.0021583.g001
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Cells were treated with 0.5 umol/L DZNep for 72 h. Cells were
collected and lysed in RIPA buffer as described previously[15].
Equal amounts of protein were separated on SDS–polyacrylamide
gels and transferred to PVDF membranes. The blots were probed
with antibodies against EZH2 (#3147), Cleaved Caspase-3
(Asp175) (#9661), Caspase-8 (#9746) and Caspase-9 (#9508)
from Cell Signaling Technology. Antibodies against Bcl-2 (sc-509),
PARP (sc-8007), H3 (sc-10809) and b-Actin (sc-69879) were from
Santa Cruz Biotechnology. The antibody against ALOX5
(#160402) was from Cayman Chemical. The antibody against
H3K27Me3 (#07-449) was from Millipore. Western Blotting
Luminol Reagent (sc-2048) was used for detection on film from
Santa Cruz Biotechnology.
Methylcellulose colony formation assay
Methylcellulose media (H4230, MethoCultH, StemCell Tech-
nologies) consisted of 1% methylcellulose, 30% fetal bovine serum
(FBS), 100 U/mL penicillin and 100 mg/mL streptomycin, and
1% bovine serum. Cells were plated in duplicate at a density of
1,500 or 3,000 cells/mL in 0.4 mL volume in 24-well plates.
Plates were incubated at 37uC, 5% CO2, and $95% humidity
(provided by a water dish) for 14 days. To observe colonies, cells
were stained with 0.5 mg/mL metabolizable tetrazolium salt
(MTT, M2003, Sigma-Aldrich), 100 mL/well. After incubating at
37uC, 5% CO2 for 1 h, colonies of more than 30 cells were
counted. For photomicrographs, plates were viewed with an
Olimpus IX71 inverted microscope at 40X magnification. Images
were acquired using a digital camera DP71 and software DP
Controller.
Analysis of ALOX5 expression in MM patient samples
The ALOX5 expression analysis was performed on a large gene
expression dataset from the University of Arkansas Medical School
that is available through the Gene Expression Omnibus. Raw
expression value was obtained from GEO GSE 2658 and 5900.
The expression values for probes representing ALOX5 on the
U133plus 2.0 chip were first log-transformed and median
centered, and then a composite relative expression value for
ALOX5 for each of patients was obtained by taking the median
expression across these probes. The expression value of 22 normal
plasma cells (NPC) and 351 newly diagnosed MM was analyzed.
The mean+2 standard deviation (SD) was used as the upper limit
of normal expression.
Vector construction
Sequences encoding short hairpin RNA (shRNA) were cloned
into pLKO.1 vector (gift of Prof. Robert A. Weinberg, Whitehead
Institute for Biomedical Research, Cambridge, MA). The shRNA
against ALOX5(shALOX5) sequence: 59 ATCCAGCTGGTCA-
GAATCGAGAA 39. The shRNA against Bcl-2 sequences: sh#82,
59 CATTATAAGCTGTCGCAGAGG 39;s h #83, 59 TGTGG-
ATGACTGAGTACCTGA 39. The control shRNA against
luciferase (shLuc) is from Prof. Robert A Weinberg. The sequence
Figure 2. ALOX5 is differentially expressed in MM cells being sensitive to DZNep. Cells were treated with 0.5 mmol/L DZNep for 48 h. Total
RNA was extracted using the Qiagen RNeasy Mini kit. (A) The cDNA microarray analysis was done to evaluate gene expression changes in response to
DZNep treatment. Heat map showed the relative expression levels of the top 20 probe sets that were differentially expressed between DZNep-
sensitive and DZNep-insensitive MM cell lines. ALOX5 was most down-regulated in DZNep-sensitive cell lines. Red, relatively high expression; green,
relatively low expression. (B) Quantitative levels of differentially expressed ALOX5. The ALOX5 was determined by quantitative RT-PCR. Colunms,
mean; bars, SE. Average CT values were first normalized against the housekeeping gene b-Actin and converted to the induced fold change relative to
the vehicle control.
doi:10.1371/journal.pone.0021583.g002
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pLN1 vector (derived from pLKO.1 by replacing U6 promoter
with CMV promoter). All clones were verified by sequencing.
Virus production and infection
Lentivirus infection was performed as previously described.[16]
Briefly, lentiviruses were produced by transiently cotransfecting
293T cells with the shRNA-expressing lentivirus vector, packaging
plasmid pCMV-dR8.2 dvpr and VSV-G envelope plasmid
pCMV-VSVG (gifts of Prof. Robert A. Weinberg) using Fugene
6 (Roche Diagnostics) according to the manufacturers’ instruc-
tions. Cells were infected with lentiviruses in the presence of 8 mg/
mL polybrene (Sigma-Aldrich). The NCI-H929 cell line overex-
pressing ALOX5 was generated using puromycin (3 mg/ml,
Sigma-Aldrich) selection.
Statistical Analysis
Results were expressed as mean values 6 SD, and t-test was
used for evaluating statistical significance. Results were considered
to be significant when p,0.05.
Results
MM cell lines display differing degree of sensitivity to
DZNep
To determine the sensitivity to DZNep, cells were treated with
different concentrations of DZNep, and cell proliferation was
measured by MTS colorimetric assay (Fig. 1A). Using this
approach, NCI-H929 and MM.1S, 2 of the 8 cell lines tested, were
very sensitive to DZNep-induced growth inhibition in the
nanomolar range. Cell apoptosis induced by DZNep was
determined by subdiploid DNA content analysis using flow
cytometry. Sub-G1 fraction undergoing apoptosis was significantly
increased after DZNep treatment in NCI-H929 and MM.1S,
while a minor to moderate increase in apoptosis was observed in
the relatively insensitive cell lines. (Fig. 1B). Because there are
MM cell lines that are both sensitive and insensitive to DZNep, we
had the opportunity to examine the molecular mechanisms of
sensitivity to DZNep within a similar tumor type.
ALOX5 is differentially expressed in MM cells according
to DZNep sensitivity
Two sensitive MM cell lines (MM.1S and NCI-H929) and two
relatively insensitive MM cell lines (KMS18 and OPM-2) were
profiled on cDNA microarrays after exposure to vehicle control or
DZNep. Many more transcripts were differentially expressed in
response to DZNep in sensitive cell lines than in insensitive cell
lines (Fig. S1A, Tables S2, S3, S4). Seventy-three genes were
significantly up-regulated and 113 genes were significantly down-
regulated in both of the sensitive cell lines. Gene ontology analysis
revealed that these genes were remarkably enriched for their roles
in cellular metabolism (Fig. S1B), suggesting cellular metabolism
may play a vital role in MM cell sensitivity to DZNep induced
apoptosis. The arachidonate 5-lipoxygenase (ALOX5) was among
the genes most down-regulated by DZNep treatment (Fig. 2A).
ALOX5 has previously been linked to leukemia stem cells and
cancer-related signaling pathways [17,18,19,20,21]. The differen-
tial expression of ALOX5 indicates a potential role in determining
sensitivity to DZNep in MM. Differential expression of ALOX5
was confirmed by quantitative RT-PCR (Fig. 2B). The magnitude
of decreased expression of ALOX5 is similar in MM.1S and NCI-
H929, but baseline levels of ALOX5expression are higher in NCI-
H929 compared with MM.1S.
DZNep reduces EZH2 and ALOX5 levels, and induces
caspase-dependent cell apoptosis
DZNep treatment has been demonstrated to decrease levels of
EZH2 in solid tumors and acute myeloid leukemia[6,7].
Consistent with these reports, treatment with DZNep also reduced
protein levels of EZH2 in NCI-H929, MM.1S, KMS18 and
OPM-2 (Fig. 3 A). H3K27Me3 levels were also decreased in
KMS18 and OPM-2 but not in the two sensitive cell lines,
Figure 3. Analysis of DZNep effects by Western-blot and RT-
PCR. DZNep reduced EZH2 and ALOX5 levels, and induced caspase-
dependent cell apoptosis. Cells were treated with 0.5 umol/L DZNep for
72 h, and then whole-cell lysates were analyzed by Western-blot
analysis. b-Actin was used as an internal control. Treatment with DZNep
reduced protein levels of EZH2 in MM cells. ALOX5 was over-expressed
in H929 and was down-regulated greatly by DZNep treatment. In H929
and MM1.S, DZNep efficiently induced caspase-3 activation and the
cleavage of PARP. Furthermore, DZNep treatment induced caspase-8
activation and had little effect on full-length caspase-9 levels.
doi:10.1371/journal.pone.0021583.g003
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cells is not mediated through its effect on EZH2 or H3K27Me3.
This result also suggests that proteins other than EZH2 may be
responsible for the H3K27 trimethylation. Consistent with real-
time PCR results, ALOX5 was over-expressed in NCI-H929 and
decreased greatly by DZNep treatment on western blot. The other
3 cell lines had low levels of ALOX5 which was also decreased by
DZNep.
To understand the mechanisms of DZNep-induced cell death in
MM cells, we examined the involvement of caspase in cell death.
In NCI-H929 and MM.1S, DZNep efficiently induced caspase-3
activation and the cleavage of PARP, a substrate of caspase-3.
Furthermore, DZNep treatment induced caspase-8 activation and
had little effect on caspase-9 activation, suggesting DZNep might
induce apoptosis via the death receptor signaling pathway.
Sensitivity to DZNep is modulated by expression levels of
ALOX5
To investigate whether ALOX5 is directly associated with
DZNep induced apoptosis, we generated the cell line of NCI-
H929/ALOX5 overexpressing ALOX5. The proliferation assay
indicated that overexpression of ALOX5 reduced sensitivity to
DZNep and resulted in 3.2-fold increase of IC50 compared with
vector control (Fig. 4A). To assay long-term effect of DZNep, we
cultured control and NCI-H929/ALOX5 cells in methylcellulose
with DZNep. NCI-H929/ALOX5 cells exhibited resistance to
colony formation inhibition relative to control (Fig. 4B and Fig.
S3A and S3B). Western-blot analysis showed a marked increase
in the expression levels of ALOX5 in NCI-H929/ALOX5, and
high levels of ectopic ALOX5 reduced PARP cleavage upon
DZNep treatment (Fig. 4C). These data indicated that forced
ectopic expression of ALOX5 could reduce sensitivity to DZNep.
To determine the effect of ALOX5 downregulation in cell
viability, NCI-H929 was infected with the shALOX5. The
shALOX5 mediated a significant decrease in ALOX5 mRNA
and protein levels in NCI-H929 relative to a control shLuc (Fig. S2
and Fig. 4D). Similar to effect of DZNep, the shALOX5 also
induced activation of caspase-8 and caspase-3 and cleavage of
PARP, and had little effect on caspase-9 activation (Fig. 4D). Flow
cytometric analysis indicated a significant increase of apoptosis after
shALOX5 treatment in NCI-H929, while a minor increase in
apoptosis was observed in controlcell line KMS18 (Fig. 4E). Taken
Figure 4. Modulation of ALOX5 expression affects sensitivity to DZNep in NCI-H929 cells. ()A NCI-H929 cells expressing the ectopic
ALOX5 were treated with DZNep for 72 h. The proliferation was determined using the MTS colorimetric assay. * indicates p,0.05, and ** indicates
p,0.01. (B) Colony formation assay. Cells were treated with DZNep and cultured in methylcellulose media for 14 days. Average colony counts are
presented. Data represent the mean 6 SD derived from 3 separate experiments with duplicate wells per condition. (C) Western-blot analysis. Cells
were also infected with shRNA control or shALOX5. (D) After 72 h, total cell lysates were prepared and Western-blot analysis was performed. (E)
Apoptosis was measured by flow cytometric sub-G1 analysis.The shALOX5 treatment induced apoptosis in NCI-H929, while it had little effect on
DZNep resistance in KMS18.
doi:10.1371/journal.pone.0021583.g004
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may contribute to cell viability of NCI-H929, and have the
functional significance as a mediator of DZNep death response.
ALOX5 is aberrantly expressed in a subset of MM Patients
As DZNep induce apoptosis in myeloma cells in large parts
through attenuating elevated expression of ALOX5, we wanted to
see if ALOX5 is also aberrantly expressed in human MM. We
assessed a large gene expression dataset from the University of
Arkansas Medical School that is available through the Gene
Expression Omnibus (GSE2658 and GSE5900), and found that
ALOX5 expression was significantly higher in MM compared to
NPC (p-value =0.002). Taking mean+2SD as the upper limit of
normal expression, 187 of 351 (53%) MM patients have abnormal
elevated expression of ALOX5 (Fig. 5). This suggests that our
finding in the myeloma cell lines is potentially applicable to a
subset of MM patients.
Cotreatment with DZNep and ABT-737 synergistically
inhibits growth and induces apoptosis of DZNep
insensitive MM cells
Bcl-2 is widely expressed in MM cell lines and primary patient
samples and is correlated with resistance to chemotherapeutics
[22,23,24,25]. We hypothesize that Bcl-2 may also be associated
with DZNep insensitivity in MM. As expected, elevated expression
of Bcl-2 was detected in KMS18 and OPM-2 (Fig. 3). To see if
inhibition of Bcl-2 can re-sensitize the resistant cells to DZNep, we
determined the combined effects of DZNep and ABT-737, a Bcl-2
inhibitor, in MM cells. MTS assay demonstrated that, compared
with each agent alone, combined treatment with DZNep and
ABT-737 synergistically inhibited growth of KMS18 (DZNep at
0.25 or 0.5 mM/L) and OPM-2 cells, as indicated by combination
indices of less than 1.0 (Fig. 6A, 6B, and Table 1). Colony
formation assay indicated that KMS18 and OPM-2 cells exhibited
a striking loss of colony formation upon cotreatment with DZNep
and ABT-737 (Fig. 6C and Fig. S3C and S3D). In addition,
cotreatment with DZNep and ABT-737 decreased Bcl-2 and bcl-
xL levels, and induced more PARP cleavage in KMS18 and
OPM-2 cells (Fig. 6D). ABT-737 treatment had little effect on
Mcl-1 levels. This is consistent with a previous study that showed
high affinity binding of ABT-737 to Bcl-2 and bcl-xL, but not to
the less homologous protein Mcl-1 [26]. In accordance with the
synergistic effect of ABT-737 with DZNep, Bcl-2 shRNA
treatment could also increase sensitivity to DZNep (Fig. S4),
Previous reports showed ABT-737 disrupted an intracellular
Bcl-2 family protein–protein interaction [26], while our western-
blot analysis indicated ABT-737 could also induce Bcl-2 cleavage,
represented by a small fragment recognized by Bcl-2 antibody. As
Bcl-2 could be cleaved by caspases and cleavage of Bcl-2 could
further activate downstream caspases [27,28], and ABT-737 could
induce activation of caspases in MM cell lines [29,30], we
examined whether ABT-737 induced Bcl-2 cleavage by a caspase-
dependent pathway. As expected, cleavage of Bcl-2 induced by
Figure 5. Expression of ALOX5 in MM Patients. Raw expression value was obtained from GEO GSE 2658 and 5900. The expression values for
probes representing ALOX5 on the U133plus 2.0 chip were first log-transformed and median centered, and then a composite relative expression value
for ALOX5 for each patient was obtained by taking the median expression across these probes. This relative expression value is represented on the Y
axis. The expression value of 22 NPC and 351 newly diagnosed MM are highlighted ranked from low to high expression. The horizontal dotted line
represents the mean +2SD expression value among the NPC.
doi:10.1371/journal.pone.0021583.g005
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inhibitor Z-VAD-FMK (Fig. 6E).
Discussion
DZNep was previously reported to be a selective inhibitor of
H3K27 and H4K20 trimethylation [6]. The extended study
showed that DZNep globally inhibited histone methylation and
was not selective [31]. Because there are multiple epigenetic
mechanisms that deregulate gene expression during carcinogen-
esis, a molecule such as DZNep that inhibits multiple marks may
be useful in epigenetic therapy.
MM is an incurable hematologic malignancy characterized by
recurrent chromosomal translocations [32,33]. MMSET (multiple
myeloma SET domain) was identified as a gene involved in the
t(4;14)(p16;q32) translocation affecting approximately 15% pa-
tients [34,35]. This subtype of myeloma has a poor prognosis with
frequent relapse after autologous stem-cell transplantation
[34,36,37]. MMSET contains a SET domain that is found in
many histone methyltransferases and determines their enzymatic
activity[38]. MMSET has been shown to be a transcriptional
corepressor and increase H4K20 trimethylation [39], so we
hypothesized that DZNep should be useful for epigenetic therapy
against MM with t(4;14). However, our proliferation and apoptosis
assays indicated DZNep sensitivity was not associated with t(4;14)
in MM (Table S5). In addition, the sensitivity of myeloma cells to
DZNep is not directly related to inhibition of EZH2 or H3K27
trimethylation, suggesting the DZNep may also act through non-
epigenetic mechanisms. The precise mechanism of drug activity in
myeloma remains elusive and is being actively pursued by our
group.
Nevertheless, insights into the determinants of DZNep sensitiv-
ity was derived from gene expression array analysis of MM cells
treated with vehicle control or DZNep. Transcripts differentially
Figure 6. Cotreatment with DZNep and ABT-737 synergistically inhibits growth and induces apoptosis of DZNep insensitive MM
cells. (A) Analysis of dose-effect relationship for DZNep (500 nmol/L) and ABT-737 (500 or 1000 nmol/L) for the proliferation after 72 h of exposure
in MM cells. The proliferation was determined by MTS colorimetric assay. Data represent the mean 6 SD derived from 3 separate experiments with
triplicate wells per condition. After this, the CI values were calculated. CI ,1, CI =1, and CI .1 represent synergy, additivity, and antagonism of the 2
agents, respectively. (B) Colony formation assay. Data represent the mean 6 SD derived from 3 separate experiments with duplicate wells per
condition. (C) After 72 h treatments, total cell lysates were prepared and Western-blot analysis was performed. (D) After treatment with ABT-737 for
48 h, Bcl-2 levels were determined by Western-blot. The Bcl-2 cleavage was inhibited by 1 h of preincubation with a pan-caspase inhibitor Z-VAD-
FMK (Promega).
doi:10.1371/journal.pone.0021583.g006
Table 1. The combination index (CI) for DZNep and ABT-737
combination.
DZNep (mM/L) ABT-737 (mM/L) I/KMS18 I/OPM-2
0.25 0.25 0.63 0.013
0.25 0.5 0.694 0.006
0.25 1 0.909 0.026
0.5 0.25 0.797 0.007
0.5 0.5 0.876 0.01
0.5 1 1.048 0.034
1 0.25 1.245 0.008
1 0.5 1.322 0.011
1 1 1.432 0.021
Note; A CI of less than, equal to, and more than 1 indicates synergy, additivity,
and antagonism, respectively.
doi:10.1371/journal.pone.0021583.t001
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enriched for their roles in cellular metabolism, suggesting cellular
metabolism might play a vital role in MM cell sensitivity to
DZNep induced apoptosis. Previous studies showed that metabolic
pathways are not only involved in the proliferation of cancer cells,
but also regulated their apoptosis [40]. ALOX5, the most down-
regulated gene by DZNep in sensitive MM cells, is a member of
the lipoxygenase gene family and plays an essential role in the
biosynthesis of leukotrienes from arachidonic acid [41]. Several
groups have examined the role of ALOX5 pathway in
carcinogenesis and have shown that it plays an important role in
promoting tumor growth and survival [17,19,20,21,42]. Recently
it was shown that the loss of ALOX5 gene impaired leukemia stem
cells and prevented chronic myeloid leukemia in mice [18]. These
prompted us to determine whether overexpression of ALOX5 is
associated with DZNep sensitivity. Our studies indicated DZNep
treatment could decrease ALOX5 level, and ectopic expression of
ALOX5 reduced sensitivity to DZNep in NCI-H929. Further-
more, knocking down ALOX5 could also induce apoptosis with
activation of caspases. These results suggest that ALOX5 has the
functional significance as a mediator of DZNep induced apoptosis.
However, ectopic expression of ALOX5 incompletely prevents
NCI-H929 cells from DZNep induced apoptosis, so the apoptosis
might depend on the change of multiple proteins or signaling
pathways. Several striking differences such as FADS1 and SCD5
involved in cellular metabolism were also observed in DZNep
sensitive cell lines in addition to the changes in ALOX5 (Table
S2).
The overexpression of Bcl-2 is almost universal in MM cell lines
and primary patient samples and promotes inappropriate survival
leading to resistance to therapy with interferon, dexamethasone,
etoposide, doxorubicin and bortezomib[22,23,24,25]. ABT-737 is a
small-molecule inhibitor designed to specifically inhibit antiapopto-
tic proteins of the Bcl-2 family. This molecule is a BH3 (Bcl-2
homology region 3) mimetic that binds with high affinity to Bcl-xL,
Bcl-2 and Bcl-w. Binding of ABT-737 to a hydrophobic groove on
Bcl-2 family proteins prevents binding of Bax, tilting the balance of
pro- and antiapoptotic molecules in favor of cellular apoptosis
[26,29]. Previous studies reveal that ABT-737 synergizes with a
range of cytotoxic chemotherapy agents [26,43,44]. We found that
Bcl-2 was overexpressed in DZNep insensitive cell lines and
combined treatment with DZNep and ABT-737 synergistically
induced apoptosis in these cells. This also suggested that
overexpression of Bcl-2 might be associated with DZNep insensi-
tivity. Although ABT-737 inhibits antiapoptotic functions of Bcl-2
family through competing with BAD for docking to the hydropho-
bic groove of Bcl-2/Bcl-xL, thus increasing activity of pro-apoptotic
BH3 proteins, we found that ABT-737 could also promote Bcl-2
cleavage, represented by a small fragment recognized by Bcl-2
antibody through a caspase dependent pathway.
In conclusion, this study showed that one of the determinants of
DZNep efficacy in MM is the ability to down-regulate elevated
ALOX5 levels. As ALOX5 is over-expressed in a substantial
subset of MM patients, this may be is viable therapeutic strategy in
a subset of MM. In addition, DZNep insensitivity might be
associated with the overexpression of Bcl-2, and the combination
of ABT-737 and DZNep could synergistically induced apoptosis in
DZNep insensitive MM.
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Figure S1 The cDNA microarray analysis of gene
expression changes in response to DZNep treatment.
(A) The column diagram showing the numbers of differentially
expressed genes in DZNep-treated cell lines. Much more number
of transcripts were differentially expressed in response to DZNep
in sensitive cell lines than in insensitive cell lines. (B) Gene
ontology (GO) assignments of biological process of genes. GO
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Figure S2 NCI-H929 cells were infected with shRNA
control or shALOX5. After 48 h, ALOX5 mRNA level was
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media. Cells were plated in duplicate at a density of 1,500 or
3,000 cells/mL in 0.4 mL volume in 24-well plates. Plates were
incubated at 37uC, 5% CO2, and $95% humidity for 14 days. To
observe colonies, cells were stained with 0.5 mg/mL metabolizable
tetrazolium salt. After incubating at 37uC, 5% CO2 for 1 h, images
wereacquiredat40XmagnificationwithanOlimpusIX71inverted
microscope. Each experiment was performed 3 times, and
representative examples are shown. (A) and (B) Ectopic expression
of ALOX5 reduced sensitivity to DZNep. (C) and (D) Cotreat-
ment with DZNep and ABT-737 synergistically reduced colony
formation in KMS18 and OPM-2.
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Figure S4 Potentiation effect of Bcl-2 shRNA with
DZNep in KMS18 and OPM-2 MM cells. Cells were treated
with Bcl-2 shRNAs and cultured for 3 days with or without DZNep
treatment. Luc, control shRNA; #82 and #83, Bcl-2 shRNA. (A)
and (B) Bcl-2 shRNAs increased sensitivity to DZNep. The
proliferationwas determined by MTS colorimetric assay (Promega).
Data represent the mean 6 SD derived from 3 separate
experiments with triplicate wells per condition. (C) Quantitative
RT-PCR analysis of Bcl-2 mRNA level on 48 h of Bcl-2 shRNA
treatment. Colunms, mean; bars, SE. Average CT values were first
normalized against the housekeeping gene b-Actin and converted to
theinduced foldchangerelativeto the vehiclecontrol.(D)Western-
blot analysis of apoptosis and Bcl-2 expression.
(DOCX)
Table S1 Primer Sequences for quantitative PCR.
(XLSX)
Table S2 Specially differentially expressed genes (fold
changes .2) in sensitive MM cell lines (H929 and
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t(4;14) translocation in MM.
(XLSX)
Author Contributions
Conceived and designed the experiments: ZX WJC. Performed the
experiments: ZX CB LLC SCL WJC. Analyzed the data: ZX CB GH JZ
WJC. Contributed reagents/materials/analysis tools: QY C-SC. Wrote the
paper: ZX WJC.
DZNep in Multiple Myeloma Cells
PLoS ONE | www.plosone.org 8 June 2011 | Volume 6 | Issue 6 | e21583References
1. Glazer RI, Knode MC, Tseng CK, Haines DR, Marquez VE (1986) 3-
Deazaneplanocin A: a new inhibitor of S-adenosylhomocysteine synthesis and its
effects in human colon carcinoma cells. Biochem Pharmacol 35: 4523–4527.
2. Glazer RI, Hartman KD, Knode MC, Richard MM, Chiang PK, et al. (1986) 3-
Deazaneplanocin: a new and potent inhibitor of S-adenosylhomocysteine
hydrolase and its effects on human promyelocytic leukemia cell line HL-60.
Biochem Biophys Res Commun 135: 688–694.
3. Bray M, Driscoll J, Huggins JW (2000) Treatment of lethal Ebola virus infection
in mice with a single dose of an S-adenosyl-L-homocysteine hydrolase inhibitor.
Antiviral Res 45: 135–147.
4. De Clercq E, Cools M, Balzarini J, Marquez VE, Borcherding DR, et al. (1989)
Broad-spectrum antiviral activities of neplanocin A, 3-deazaneplanocin A, and
their 59-nor derivatives. Antimicrob Agents Chemother 33: 1291–1297.
5. Mayers DL, Mikovits JA, Joshi B, Hewlett IK, Estrada JS, et al. (1995) Anti-
human immunodeficiency virus 1 (HIV-1) activities of 3-deazaadenosine
analogs: increased potency against 39-azido-39-deoxythymidine-resistant HIV-1
strains. Proc Natl Acad Sci U S A 92: 215–219.
6. Tan J, Yang X, Zhuang L, Jiang X, Chen W, et al. (2007) Pharmacologic
disruption of Polycomb-repressive complex 2-mediated gene repression
selectively induces apoptosis in cancer cells. Genes Dev 21: 1050–1063.
7. Fiskus W, Wang Y, Sreekumar A, Buckley KM, Shi H, et al. (2009) Combined
epigenetic therapy with the histone methyltransferase EZH2 inhibitor 3-
deazaneplanocin A and the histone deacetylase inhibitor panobinostat against
human AML cells. Blood 114: 2733–2743.
8. Parkin DM, Bray F, Ferlay J, Pisani P (2005) Global cancer statistics, 2002. CA
Cancer J Clin 55: 74–108.
9. Raab MS, Podar K, Breitkreutz I, Richardson PG, Anderson KC (2009)
Multiple myeloma. Lancet 374: 324–339.
10. Xie Z, Choong PF, Poon LF, Zhou J, Khng J, et al. (2008) Inhibition of CD44
expression in hepatocellular carcinoma cells enhances apoptosis, chemosensitiv-
ity, and reduces tumorigenesis and invasion. Cancer Chemother Pharmacol 62:
949–957.
11. Zhou J, Pan M, Xie Z, Loh SL, Bi C, et al. (2008) Synergistic antileukemic
effects between ABT-869 and chemotherapy involve downregulation of cell
cycle-regulated genes and c-Mos-mediated MAPK pathway. Leukemia 22:
138–146.
12. Ozvaran MK, Cao XX, Miller SD, Monia BA, Hong WK, et al. (2004)
Antisense oligonucleotides directed at the bcl-xl gene product augment
chemotherapy response in mesothelioma. Mol Cancer Ther 3: 545–550.
13. Riccardi C, Nicoletti I (2006) Analysis of apoptosis by propidium iodide staining
and flow cytometry. Nat Protoc 1: 1458–1461.
14. Mi H, Lazareva-Ulitsky B, Loo R, Kejariwal A, Vandergriff J, et al. (2005) The
PANTHER database of protein families, subfamilies, functions and pathways.
Nucleic Acids Res 33: D284–288.
15. Kho PS, Wang Z, Zhuang L, Li Y, Chew JL, et al. (2004) p53-regulated
transcriptional program associated with genotoxic stress-induced apoptosis. J Biol
Chem 279: 21183–21192.
16. Godar S, Ince TA, Bell GW, Feldser D, Donaher JL, et al. (2008) Growth-
inhibitory and tumor- suppressive functions of p53 depend on its repression of
CD44 expression. Cell 134: 62–73.
17. Belfiore MC, Natoni A, Barzellotti R, Merendino N, Pessina G, et al. (2007)
Involvement of 5-lipoxygenase in survival of Epstein-Barr virus (EBV)-converted
B lymphoma cells. Cancer Lett 254: 236–243.
18. Chen Y, Hu Y, Zhang H, Peng C, Li S (2009) Loss of the Alox5 gene impairs
leukemia stem cells and prevents chronic myeloid leukemia. Nat Genet 41:
783–792.
19. Ghosh J (2003) Inhibition of arachidonate 5-lipoxygenase triggers prostate
cancer cell death through rapid activation of c-Jun N-terminal kinase. Biochem
Biophys Res Commun 307: 342–349.
20. Melstrom LG, Bentrem DJ, Salabat MR, Kennedy TJ, Ding XZ, et al. (2008)
Overexpression of 5-lipoxygenase in colon polyps and cancer and the effect of 5-
LOX inhibitors in vitro and in a murine model. Clin Cancer Res 14:
6525–6530.
21. Zhou GX, Ding XL, Huang JF, Zhang H, Wu SB (2007) Suppression of 5-
lipoxygenase gene is involved in triptolide-induced apoptosis in pancreatic tumor
cell lines. Biochim Biophys Acta 1770: 1021–1027.
22. Puthier D, Derenne S, Barille S, Moreau P, Harousseau JL, et al. (1999) Mcl-1
and Bcl-xL are co-regulated by IL-6 in human myeloma cells. Br J Haematol
107: 392–395.
23. Sangfelt O, Osterborg A, Grander D, Anderbring E, Ost A, et al. (1995)
Response to interferon therapy in patients with multiple myeloma correlates
with expression of the Bcl-2 oncoprotein. Int J Cancer 63: 190–192.
24. Feinman R, Koury J, Thames M, Barlogie B, Epstein J, et al. (1999) Role of NF-
kappaB in the rescue of multiple myeloma cells from glucocorticoid-induced
apoptosis by bcl-2. Blood 93: 3044–3052.
25. Tu Y, Xu FH, Liu J, Vescio R, Berenson J, et al. (1996) Upregulated expression
of BCL-2 in multiple myeloma cells induced by exposure to doxorubicin,
etoposide, and hydrogen peroxide. Blood 88: 1805–1812.
26. Oltersdorf T, Elmore SW, Shoemaker AR, Armstrong RC, Augeri DJ, et al.
(2005) An inhibitor of Bcl-2 family proteins induces regression of solid tumours.
Nature 435: 677–681.
27. Cheng EH, Kirsch DG, Clem RJ, Ravi R, Kastan MB, et al. (1997) Conversion
of Bcl-2 to a Bax-like death effector by caspases. Science 278: 1966–1968.
28. Kirsch DG, Doseff A, Chau BN, Lim DS, de Souza-Pinto NC, et al. (1999)
Caspase-3-dependent cleavage of Bcl-2 promotes release of cytochrome c. J Biol
Chem 274: 21155–21161.
29. Kline MP, Rajkumar SV, Timm MM, Kimlinger TK, Haug JL, et al. (2007)
ABT-737, an inhibitor of Bcl-2 family proteins, is a potent inducer of apoptosis
in multiple myeloma cells. Leukemia 21: 1549–1560.
30. Chauhan D, Velankar M, Brahmandam M, Hideshima T, Podar K, et al. (2007)
A novel Bcl-2/Bcl-X(L)/Bcl-w inhibitor ABT-737 as therapy in multiple
myeloma. Oncogene 26: 2374–2380.
31. Miranda TB, Cortez CC, Yoo CB, Liang G, Abe M, et al. (2009) DZNep is a
global histone methylation inhibitor that reactivates developmental genes not
silenced by DNA methylation. Mol Cancer Ther 8: 1579–1588.
32. Bergsagel PL, Chesi M, Nardini E, Brents LA, Kirby SL, et al. (1996)
Promiscuous translocations into immunoglobulin heavy chain switch regions in
multiple myeloma. Proc Natl Acad Sci U S A 93: 13931–13936.
33. Bergsagel PL, Kuehl WM (2005) Molecular pathogenesis and a consequent
classification of multiple myeloma. J Clin Oncol 23: 6333–6338.
34. Keats JJ, Reiman T, Belch AR, Pilarski LM (2006) Ten years and counting: so
what do we know about t(4;14)(p16;q32) multiple myeloma. Leuk Lymphoma
47: 2289–2300.
35. Chesi M, Nardini E, Lim RS, Smith KD, Kuehl WM, et al. (1998) The t(4;14)
translocation in myeloma dysregulates both FGFR3 and a novel gene, MMSET,
resulting in IgH/MMSET hybrid transcripts. Blood 92: 3025–3034.
36. Keats JJ, Reiman T, Maxwell CA, Taylor BJ, Larratt LM, et al. (2003) In
multiple myeloma, t(4;14)(p16;q32) is an adverse prognostic factor irrespective of
FGFR3 expression. Blood 101: 1520–1529.
37. Chang H, Sloan S, Li D, Zhuang L, Yi QL, et al. (2004) The t(4;14) is associated
with poor prognosis in myeloma patients undergoing autologous stem cell
transplant. Br J Haematol 125: 64–68.
38. Dillon SC, Zhang X, Trievel RC, Cheng X (2005) The SET-domain protein
superfamily: protein lysine methyltransferases. Genome Biol 6: 227.
39. Marango J, Shimoyama M, Nishio H, Meyer JA, Min DJ, et al. (2008) The
MMSET protein is a histone methyltransferase with characteristics of a
transcriptional corepressor. Blood 111: 3145–3154.
40. Hsu PP, Sabatini DM (2008) Cancer cell metabolism: Warburg and beyond.
Cell 134: 703–707.
41. Peters-Golden M (1998) Cell biology of the 5-lipoxygenase pathway. Am J Respir
Crit Care Med 157: S227-231; discussion S231-222, S247-228.
42. Ghosh J, Myers CE (1998) Inhibition of arachidonate 5-lipoxygenase triggers
massive apoptosis in human prostate cancer cells. Proc Natl Acad Sci U S A 95:
13182–13187.
43. Mason KD, Khaw SL, Rayeroux KC, Chew E, Lee EF, et al. (2009) The BH3
mimetic compound, ABT-737, synergizes with a range of cytotoxic chemother-
apy agents in chronic lymphocytic leukemia. Leukemia 23: 2034–2041.
44. Pandit B, Gartel AL (2010) New potential anti-cancer agents synergize with
bortezomib and ABT-737 against prostate cancer. Prostate 70: 825–833.
DZNep in Multiple Myeloma Cells
PLoS ONE | www.plosone.org 9 June 2011 | Volume 6 | Issue 6 | e21583